Atwood & Palmer’s RxSight RXST Stock Holding History

Atwood & Palmer’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,600	Closed	-$27.1K	–	551
2025 Q4	$27.1K	Hold	2,600	–	–	﹤0.01%	293
2025 Q3	$23.4K	Buy	+2,600	New	+$22.8K	﹤0.01%	322

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Atwood & Palmer's RXST Position: Q1 2026 in Review

Atwood & Palmer sold out of RxSight (RXST) in Q1 2026, closing a stake of 2,600 shares — an estimated $27.1K sold.

Atwood & Palmer first reported a position in RXST in Q3 2025 and held it in 2 quarters. The position peaked at $27.1K in Q4 2025. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

Atwood & Palmer reported no remaining RxSight position as of Q1 2026 after selling out during the quarter.
Atwood & Palmer sold 2,600 RxSight shares in Q1 2026, an estimated $27.1K.
Atwood & Palmer first reported a position in RxSight in Q3 2025 and held it in 2 quarters.
Atwood & Palmer's RxSight position peaked at $27.1K in Q4 2025.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Atwood & Palmer's 13F filing for Q1 2026, filed 15 Apr 2026.